STATUTORY INSTRUMENTS

2015 No. 704

DANGEROUS DRUGS

The Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015

Made - - - -	*12th March 2015*
Laid before Parliament	*17th March 2015*
Coming into force - -	*31st May 2015*

The Secretary of State, after consultation with the Advisory Council on the Misuse of Drugs, makes the following Order in exercise of the powers conferred by section 7(4) and (5) of the Misuse of Drugs Act 1971(**1**).

Citation, commencement and extent

1.—(1) This Order may be cited as the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 and comes into force on 31st May 2015.

(2) This Order extends to England and Wales and Scotland.

Designation of controlled drugs

2.—(1) The controlled drugs specified in Part 1 of Schedule 1 are designated as drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies.

(2) Part 2 of Schedule 1 has effect for the purpose of specifying those controlled drugs which are excepted from Part 1 of that Schedule.

Revocations

3. The Orders specified in Schedule 2 are revoked.

Home Office
12th March 2015

Lynne Featherstone
Minister of State

(**1**) 1971 c. 38.

SCHEDULE 1 Article 2

CONTROLLED DRUGS TO WHICH SECTION 7(4)
OF THE MISUSE OF DRUGS ACT 1971 APPLIES

1. The following substances and products, namely:—

(a) Bufotenine

1,4-Butanediol

Cannabinol

Cannabinol derivatives not being dronabinol or its stereoisomers

Cannabis (not being the substance specified in paragraph 4 of Part 2 of this Schedule)

Cannabis resin

Cathinone

Coca leaf

Concentrate of poppy-straw

Eticyclidine

Etryptamine

Fungus (of any kind) which contains psilocin or an ester of psilocin

Gamma-butyrolactone

Khat

Lysergamide

Lysergide and other *N*-alkyl derivatives of lysergamide

Mescaline

Methcathinone

Psilocin

Raw opium

Rolicyclidine

Tenocyclidine

(6a*R*,9*R*)-4-acetyl-*N,N*-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (ALD-52)

4-Bromo-2,5-dimethoxy-a-methylphenethylamine

1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)

3,4-dichloro-*N*-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)

(6a*R,*9*R*)-*N,N*-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (AL-LAD)

(6a*R,*9*R*)-*N,N*-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (ETH-LAD)

(6a*R,*9*R*)-*N,N*-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (PRO-LAD)

N,N-Diethyltryptamine

2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol

2,4-dimethylazetidinyl{(6a*R,*9*R*)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinolin-9-yl}methanone (LSZ)

N,N-Dimethyltryptamine

2,5-Dimethoxy-α,4-dimethylphenethylamine

N-Hydroxy-tenamphetamine

4-Methyl-aminorex

4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4'-DMAR)

(b) Any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—

(i) by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;

(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;

(iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;

(iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent;

(c) the following phenethylamine derivatives, namely—

Allyl(α-methyl-3,4-methylenedioxyphenethyl)amine

2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

2-Amino-1-(3,4-dimethoxyphenyl)ethanol

Benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine

4-Bromo-β,2,5-trimethoxyphenethylamine

N-(4-*sec*-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine

Cyclopropylmethyl(α -methyl-3,4-methylenedioxyphenethyl)amine

2-(4,7-Dimethoxy-2,3-dihydro-1*H*-indan-5-yl)ethylamine

2-(4,7-Dimethoxy-2,3-dihydro-1*H*-indan-5-yl)-1-methylethylamine

2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

2-(1,4-Dimethoxy-2-naphthyl)ethylamine

2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine

2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

α,α-Dimethyl-3,4-methylenedioxyphenethylamine

α,α-Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine

Dimethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

N-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine

4-Iodo-2,5-dimethoxy-α-methylphenethyl(dimethyl)amine

2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine

2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine

2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine

2-Methoxyethyl(α-methyl-3,4-methylenedioxyphenethyl)amine

2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine

β-Methoxy-3,4-methylenedioxyphenethylamine

1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine

1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine

2-(α-Methyl-3,4-methylenedioxyphenethylamino)ethanol

α-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine

N-Methyl-*N*-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

O-Methyl-*N*-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine

α-Methyl-4-(methylthio)phenethylamine

β,3,4,5-Tetramethoxyphenethylamine

β,2,5-Trimethoxy-4-methylphenethylamine;

(d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an *N*-alkylphenethylamine, α-methylphenethylamine, an *N*-alkyl-α-methylphenethylamine, α-ethylphenethylamine, or an *N*-alkyl-α-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substitutents;

(e) any compound (not being a compound for the time being specified in Part 2 of this Schedule) structurally derived from fentanyl by modification in any of the following ways, that is to say—

(i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;

(ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

(iii) by substitution in the piperidine ring with alkyl or alkenyl groups;

(iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;

(v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;

(vi) by replacement of the *N*-propionyl group by another acyl group;

(f) any compound (not being a compound for the time being specified in Part 2 of this Schedule) structurally derived from pethidine by modification in any of the following ways, that is to say—

(i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;

(ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;

(iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;

(iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;

(v) by formation of an *N*-oxide or of a quaternary base;